Afatinib is a type of medicine used to treat certain kinds of lung cancer. It works by blocking specific proteins that help cancer cells grow. It's usually given as a pill taken by mouth.
Every report comes from a Lived member, sent anonymously.
Have you tried Afatinib for Non-Small Cell Lung Cancer?
Afatinib, sold under the brand name Gilotrif and also available as a generic, is a targeted cancer pill for non-small cell lung cancer (NSCLC), the most common type of lung cancer. It is used when the cancer is metastatic, meaning it has spread beyond the lung. Its main use is as a first treatment for NSCLC whose tumor carries a change in a gene called EGFR (epidermal growth factor receptor). Before afatinib is started for this purpose, a sample of the tumor must be tested, and the result must show an EGFR mutation that the drug can act on. The two most common are called exon 19 deletions and L858R. Afatinib also works against several less common EGFR mutations, which is one of the main reasons it is still chosen today. It is not intended for so-called resistant EGFR mutations, where it has not been shown to help. For the common EGFR mutations, many cancer guidelines now prefer osimertinib (Tagrisso), a newer drug of the same broad type, as the first choice. Afatinib remains an accepted first-line option, and the choice can depend on the specific mutation, whether the cancer has reached the brain, side effects and access. Afatinib is also approved for a different group: people with metastatic squamous NSCLC (a subtype that starts in the flat cells lining the airways) whose cancer has grown after platinum-based chemotherapy. In that setting the benefit is smaller.
EGFR is a receptor on the surface of cells that, when switched on, tells the cell to grow and divide. In some lung cancers, a mutation in the EGFR gene leaves this switch stuck in the on position, so the tumor keeps receiving a growth signal even without the usual trigger. These tumors come to depend on that signal. Afatinib is a tyrosine kinase inhibitor, a drug that blocks the part of the receptor that passes the signal into the cell. It binds permanently to EGFR and to two related receptors, HER2 and HER4, shutting down this family of growth signals. When a tumor relies on mutated EGFR, cutting off the signal can shrink the cancer or stop it from growing for a period of time. Because normal skin, the lining of the gut and the nail beds also use EGFR to renew themselves, blocking it explains why rash, diarrhea, mouth sores and nail problems are so common. Over time most cancers find another way to grow, which is why the treatment eventually stops working for most people.
Afatinib is a tablet taken by mouth once a day, every day, for as long as it keeps the cancer under control and side effects remain manageable. The usual starting dose is 40 mg, and people with severe kidney disease generally start lower. It must be taken on an empty stomach: at least one hour before a meal or two hours after one. If a dose is missed, it can be taken later that day, but not if the next dose is due within 12 hours; in that case, skip it and do not double up. Dose changes are a normal part of treatment. More than half of people in the main trial needed a lower dose because of side effects, most often diarrhea or rash. The cancer team may pause the drug until a side effect settles and then restart at a reduced dose, in steps of 10 mg. Make these changes only with the care team rather than adjusting on your own.
Diarrhea is the most common side effect, affecting nearly everyone, and its severe form most often appears in the first six weeks. It is managed with a plan made before it starts: people are typically given an antidiarrheal such as loperamide to take at the first loose stool and to continue until stools have been normal for 12 hours, along with plenty of fluids. Tell the care team when diarrhea begins. Diarrhea that is severe or lasts despite loperamide needs prompt contact with the team, because it can cause dehydration and, in some cases, kidney damage. Skin changes are the next most common. Many people develop an acne-like rash on the face, chest and back, along with dry, itchy skin. Painful infection or swelling around the nails (paronychia) and mouth sores are also frequent, as are reduced appetite, nausea and vomiting. Protective clothing and sunscreen are advised, and the care team can help treat skin and nail problems as they arise. Blistering or peeling skin is uncommon but serious and should be reported right away. A few less common problems need prompt attention: Lung inflammation (interstitial lung disease) can occur and is occasionally fatal. Report new or worsening shortness of breath, cough or fever right away. Liver injury is checked with regular blood tests. Yellowing of the skin or eyes, dark tea-colored urine or pain in the upper right abdomen should be reported promptly. Inflammation of the clear front surface of the eye (keratitis) can cause eye pain, redness, swelling or blurred vision, which should be reported promptly. Contact lens wear raises this risk. Heart pumping problems are rare. Report worsening breathlessness with activity, swelling of the ankles or legs, a racing or pounding heartbeat, or sudden weight gain. Rarely, afatinib can cause a tear in the stomach or bowel wall. Severe abdominal pain needs immediate emergency medical care.
Afatinib can harm a developing baby. People who could become pregnant should use effective birth control during treatment and for at least two weeks after the last dose, and should tell the care team right away about a known or suspected pregnancy. Breastfeeding is not recommended during treatment or for two weeks after stopping. Afatinib may also reduce fertility in both women and men, and it is not known whether this is reversible, so anyone hoping to have children later should raise it before starting. Some medicines change how much afatinib reaches the bloodstream. Rifampin (an antibiotic used for tuberculosis), the seizure medicines carbamazepine, phenytoin and phenobarbital, and the herbal supplement St. John's wort can lower afatinib levels and may make it less effective. Others, including the antifungals ketoconazole and itraconazole, the antibiotic erythromycin, the heart medicines verapamil and amiodarone, and some HIV medicines and transplant drugs, can raise afatinib levels and worsen side effects. The team may adjust the dose when these are needed, so share a full list of prescriptions, over-the-counter drugs and supplements. Taking steroids or anti-inflammatory pain relievers such as ibuprofen or naproxen, being older, or having a history of stomach ulcers, diverticular disease or cancer in the bowel raises the risk of a bowel tear. Afatinib should be used carefully in people with a history of keratitis or severe dry eye.
For people with an EGFR mutation, afatinib often shrinks the cancer. In the main first-line trial, about half of people had measurable tumor shrinkage, compared with about one in five on chemotherapy, and the cancer was held in check for a median of about 11 months versus about 7 months. That trial did not show that people lived longer overall than with chemotherapy. Results vary widely, and some people stay on afatinib much longer than the average. The first several weeks are usually the hardest for side effects. Most people settle into a routine once diarrhea and skin care plans are in place and the dose is adjusted if needed. Regular visits include blood tests for liver and kidney function and periodic scans to check whether the cancer is responding. When scans show the cancer growing again, the team reviews the next options, sometimes with further testing of the cancer, and moves to a different treatment. Stopping afatinib is a decision made with the care team based on scans and how well it is tolerated, not something to do on your own.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Afatinib, what you've noticed, or ask the community a question.